Re: Sarcopenia is a Poor Prognostic Factor of Castration-Resistant Prostate Cancer Treated with Docetaxel Therapy

2020 ◽  
Vol 203 (1) ◽  
pp. 10-11
Author(s):  
Tomas L. Griebling
Keyword(s):  
Prostate Cancer ◽  
Prognostic Factor ◽  
Castration Resistant Prostate Cancer ◽  
Poor Prognostic Factor ◽  
Castration Resistant

The efficacy of enzalutamide for castration-resistant prostate cancer (CRPC) patients with intraductal carcinoma of the prostate (IDC-P).

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 209-209
Author(s):  
Hideji Kawanishi ◽  
Masashi Kato ◽  
Akiyuki Yamamoto ◽  
Toyonori Tsuzuki
Keyword(s):  
Prostate Cancer ◽  
Prognostic Factor ◽  
Treatment Failure ◽  
Castration Resistant Prostate Cancer ◽  
Poor Prognostic Factor ◽  
Time To Treatment ◽  
Castration Resistant ◽  
Time To Treatment Failure ◽  
Before And After ◽  
Psa Response

209 Background: Enzalutamide (ENZ) was approved to prolong survival for castration-resistant prostate cancer (CRPC) patients before and after chemotherapy. No factor was identified to predict the effectiveness of ENZ so far. .Intraductal carcinoma of the prostate (IDC-P) was newly recognized on 2017 EAU guideline and considering as a poor prognostic factor、although there has been no reports to predict the therapeutic effects of ENZ according to the presence of IDC-P. In this study, we evaluated the efficacy of ENZ for CRPC patients with or without IDC-P. Methods: We retrospectively identified 199 CRPC patients treated with ENZ from 2014 to 2018 in author-affiliated hospitals. All needle biopsy slides were reviewed by a single genitourinary pathologist and IDC-P was defined according to the criteria of McNeal at initial biopsy. Endpoint is overall survival (OS) from the time of CRPC diagnosis and time to treatment failure of ENZ. PSA response is defined as over 50% PSA decline from baseline. Results: The median patient age was 71 (range, 49–90) years. The median initial PSA was 154 ng/ml (range, 3.9–24736 ng/ml). The patients who received docetaxel were 42/199 (21%). IDC-P was detected in 98 patients (49%) at initial prostate biopsy. PSA response was 70.5% in patients without IDC-P and 53.9% in patients with IDC-P. The median OS from the time of CRPC was 37.9 and 71.5 months with and without IDC-P, respectively (P=0.013). There was no significant difference on OS in CRPC patients with IDC-P between before and after docetaxel (P=0.941). Same result was observed in CRPC patients without IDC-P (P=0.86). In time to treatment failure by ENZ, patients with IDC-P showed worse prognosis than patients without IDC-P after docetaxel (P=0.068). On the other hand, the difference disappeared before docetaxel regardless the presence of IDC-P (P=0.94). Conclusions: IDC-P is a poor prognostic factor for CRPC patients treated with ENZ. ENZ may be most effective for CRPC patients with IDC-P before chemotherapy.

scholarly journals Sarcopenia is a poor prognostic factor of castration-resistant prostate cancer treated with docetaxel therapy

2019 ◽  
Vol 7 (1) ◽  
pp. 9-14 ◽  
Author(s):  
Ayako Ohtaka ◽  
Hiroaki Aoki ◽  
Masayoshi Nagata ◽  
Mayuko Kanayama ◽  
Fumitaka Shimizu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prognostic Factor ◽  
Castration Resistant Prostate Cancer ◽  
Poor Prognostic Factor ◽  
Castration Resistant

Clinical significance of AR amplification from CF DNA among Japanese castration-resistant prostate cancer patients.

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 314-314
Author(s):  
Shinichi Sakamoto ◽  
Keisuke Ando ◽  
Nobushige Takeshita ◽  
Satoshi Yamamoto ◽  
Akira Komiya ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Multivariate Analysis ◽  
Prognostic Factor ◽  
Univariate Analysis ◽  
Independent Prognostic Factor ◽  
Serum Testosterone Level ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Number Of Patients ◽  
Significant Factors

314 Background: We study the prognostic ability of androgen receptor amplification (AR amp) from cf DNA in Japanese castration-resistant prostate cancer (CRPC) patients. Methods: Multiple sets of serums were obtained from 38 castration-resistant prostate cancer patient at Chiba University hospital. Serum cfDNA was purified using a cobas cfDNA Sample Preparation Kit. AR copy number was measured using the QX100 Droplet Digital PCR System. Factors associated with progression-free survival (PFS) and Overall Survival (OS) were statistically studied. Results: The number of patients received Enzalutamide (Enza)/Abiraterone (Abi)/Docetaxel (Doc) were 33/25/11. Regarding PFS, the presence of AR amplification, Bone Scan Index (BSI), PSA was significant factors on univariate analysis. On multivariate analysis, AR amplification was an independent prognostic factor (HR. 8.9, p=0.003). Regarding OS, PSA and AR amp was significant factors. On multivariate analysis, AR amp (HR 4.2, p=0.028) was an independent prognostic factor. AR amp was related to the young age, high bone metastasis, high PSA, while no association was identified related the visceral metastasis. Overall, the presence of AR amp was negatively related to the initial ADT periods (r=-0.28). In contrary, among primary resistance cases (initial treatment periods <1 year), AR amp positively related to the treatment periods (r=0.31). Higher nadir testosterone (>15 ng/dL) was related to the higher AR amp (p=0.0169). AR amp was related to the treatment resistance in Enza (p=0.0216), while no relation was observed in Abi or Doc. Conclusions: AR amp significantly correlated with the poor prognosis. Higher serum testosterone level may predict the presence of AR amp in cf DNA. [Table: see text]

MP28-16 PROSTATIC TISSUE ANDROGEN LEVELS AS PROGNOSTIC FACTOR FOR MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

2017 ◽  
Vol 197 (4S) ◽  
Author(s):  
Yasuhide Miyoshi ◽  
Takashi Kawahara ◽  
Mari Ohtaka ◽  
Sohgo Tsutsumi ◽  
Koichi Uemura ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prognostic Factor ◽  
Prostatic Tissue ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Androgen Levels
Sign in / Sign up

Export Citation Format

Share Document